AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1267.39% year-on-year.
Undervalued
The company’s latest PE is -52.32, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.21M shares, decreasing 29.73% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 13.46K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.34.